Specialist diagnostics partner in the Benelux
+31 (0)85 0045479 Mon–Fri 08:30–17:00 · -
Pharmacogenetics · CYP2C9
Viennalab Distributed by Goffin Diagnostics

CYP2C9 PCR Assay

Looking for a reliable and efficient way to detect CYP2C9 genetic variants in your patients? Look no further than the Viennalab CYP2C9 PCR Kit! Our RealFast™ Assay allows for simultaneous detection of CYP2C9*2 and CYP2C9*3 variants, enabling you to quickly and accurately identify patients with impaired enzyme function. With these genetic variants leading to high inter-individual dose response variability of certain drugs, particularly coumarin-based anticoagulants, it’s crucial to identify patients with low enzyme activity who are at risk of adverse drug reactions or therapeutic failure. By detecting PM phenotypes, you can better manage patient dosing and reduce the risk of severe bleeding during coumarin-based anticoagulation therapy with warfarin, acenocoumarol, and phenprocoumon. Trust in the Viennalab CYP2C9 PCR Kit to provide you with reliable and accurate results, enabling you to make informed treatment decisions for your patients. Order now and experience the convenience and efficiency of RealFast™ technology!

Real-Time PCR CE-IVD Viennalab 1 Unit (100 Reactions), 1 Unit (32 Reactions)
Technique
Real-Time PCR
Brand
Viennalab
Packaging
1 Unit (100 Reactions), 1 Unit (32 Reactions)
Download documentation

Quote-based, no public pricing. Add to your quote and our specialists put together a proposal with the right documentation, typically within 24 hours.

Product details

This kit in detail

  • Variants of CYP2C9 leads to poor metabolism (PM)
  • Patients with low enzyme activity are at risk
  • Individuals with PM phenotype are at greater risk

Looking for a reliable and efficient way to detect CYP2C9 genetic variants in your patients? Look no further than the Viennalab CYP2C9 PCR Kit! Our RealFast™ Assay allows for simultaneous detection of CYP2C9*2 and CYP2C9*3 variants, enabling you to quickly and accurately identify patients with impaired enzyme function.

With these genetic variants leading to high inter-individual dose response variability of certain drugs, particularly coumarin-based anticoagulants, it’s crucial to identify patients with low enzyme activity who are at risk of adverse drug reactions or therapeutic failure. By detecting PM phenotypes, you can better manage patient dosing and reduce the risk of severe bleeding during coumarin-based anticoagulation therapy with warfarin, acenocoumarol, and phenprocoumon.

Trust in the Viennalab CYP2C9 PCR Kit to provide you with reliable and accurate results, enabling you to make informed treatment decisions for your patients. Order now and experience the convenience and efficiency of RealFast™ technology!

  1. DNA Extraction Kit: A kit containing all the reagents necessary for the extraction of genomic DNA from a blood or saliva sample, including DNA extraction buffer, proteinase K, and magnetic beads.
  2. PCR Mix: A ready-to-use mix containing all the reagents necessary for the PCR amplification of the CYP2C9 gene region of interest.
  3. CYP2C9 Primer Mix: A mix of primers specific for the CYP2C9 gene region of interest.
  4. Probe Mix: A mix of probes specific for the detection of SNPs in the CYP2C9 gene, including variants *2 and *3.
  5. Control DNA: A synthetic DNA that is added to the sample as an internal control to ensure that the assay is working correctly.
  6. DNase/RNase-free Water: Water that has been treated to remove contaminating DNases and RNases, which can degrade the extracted DNA.

The kit also includes instructions for use, as well as a protocol for the detection of SNPs in the CYP2C9 gene using real-time PCR.

Documentation

Datasheets and regulatory documentation

Everything your quality team needs for evaluation and procurement.

Let’s talk diagnostics

Add this kit to your quote

Tell us the platforms and throughput you’re planning for and our specialists will put together a clear proposal with the right documentation, no public pricing, just a considered answer.